Nanofibrous self-gelling microspheres for heart regeneration
用于心脏再生的纳米纤维自凝胶微球
基本信息
- 批准号:10229376
- 负责人:
- 金额:$ 39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcetylationAddressAmericanAreaBiological AssayBiomimeticsBody TemperatureCardiac MyocytesCardiac developmentCardiovascular DiseasesCause of DeathCell ProliferationCell SurvivalCell TransplantationCellsCessation of lifeChromatinCouplingDataDevicesDiseaseDrug Delivery SystemsEngraftmentEnsureEnvironmentEpigenetic ProcessExtracellular MatrixExtracellular Matrix ProteinsFOXM1 geneGelGene ExpressionGenesHeartHeart failureHumanHydrogelsHypoxiaIn VitroInfarctionInjectableIschemiaLengthLuciferasesMechanicsMediatingMediator of activation proteinMethylationMicrospheresModelingModulusMolecularMyocardial InfarctionMyocardiumNanosphereNatural regenerationOxygenPatientsPharmacologyPhenotypePropertyProteoglycanPumpRNA InterferenceRattusRecoveryRecovery of FunctionRecurrenceReperfusion TherapyRoleSourceStructureSystemTechnologyTemperatureTestingTissue EngineeringTissuesTransplantationValproic AcidWeightbasecardiac regenerationcontrolled releasecopolymerdesignepigenetic drugexperimental studyheart cellheart functionhigh throughput screeningimprovedin vivoknock-downmuscle regenerationnanofibernew technologynoveloverexpressionpreservationpreventregenerativeregenerative biologyscaffoldsmall moleculesudden cardiac death
项目摘要
Nanofibrous self-gelling microspheres for heart regeneration
Cardiovascular disease (CVD) is the leading cause of death in the world today. In particular, myocardial
infarction (MI), commonly known as heart attack, results in permanent heart muscle damage or death, and is
the number one killer of heart patients. One major challenge to heart functional recovery after MI is the harsh
environment of infarcted areas, which prevents either repopulation of endogenous cells or/and
retention/integration of transplanted cells. We have developed injectable nanofibrous self-gelling microspheres
as a novel cell carrier and found they dramatically increase cell engraftment in infarcted hearts. We have also
developed novel technology for controlled release of biomolecules to enhance heart regeneration. In addition,
we have discovered that an epigenetic drug valproic acid (VPA) reduces ~50% of the infarct size when
administrated after ischemia reperfusion (IR) and preserves the pumping function of heart in a rat MI model.
We therefore hypothesize that high retention of transplanted cells and a reviving epigenetic microenvironment
for them can synergize cardiac muscle regeneration in infarcted heart, substantially improving functional
recovery. The following specific aims are proposed to test our hypothesis and develop novel regenerative heart
therapy: Aim 1. Determine the molecular mechanism of VPA in enhancing cell survival in infarcted heart. Aim 2.
Develop nanofibrous self-gelling microspheres as a carrier for cells and biomolecules. Aim 3. Regenerate
infarcted heart using VPA and cell-carrying nanofibrous self-gelling microspheres in immunodeficient rats. By
accomplishing these specific aims, we will achieve substantial new mechanistic understandings and will
develop novel and advanced technologies for heart regeneration.
用于心脏再生的纳米纤维自凝胶型微球
心血管疾病(CVD)是当今世界主要的死亡原因。尤其是心肌梗塞
心肌梗死(MI),俗称心脏病发作,会导致永久性的心肌损伤或死亡,
心脏病患者的头号杀手。心肌梗死后心脏功能恢复的一个主要挑战是严酷的
梗死区的环境,防止内源性细胞或/和
移植细胞的保留/整合。我们已经开发出可注射的纳米纤维自凝胶型微球
作为一种新的细胞载体,他们发现它们极大地增加了梗塞心脏中的细胞植入率。我们还有
开发了生物分子控制释放的新技术,以促进心脏再生。此外,
我们发现,表观遗传药物丙戊酸(VPA)在以下情况下可减少~50%的梗塞面积
在缺血再灌流(IR)后给药,并在大鼠心肌梗死模型上保留心脏的泵血功能。
因此,我们假设移植细胞的高保留率和复苏的表观遗传微环境
因为它们可以协同梗死心脏的心肌再生,显著改善功能
恢复。为了验证我们的假设和开发新的再生心脏,我们提出了以下具体目标
治疗:目的1.确定丙戊酸促进心肌梗死后细胞存活的分子机制。目标2.
开发纳米纤维自凝胶型微球作为细胞和生物分子的载体。目标3.再生
在免疫缺陷大鼠中使用VPA和携带细胞的纳米纤维自凝胶微球进行心肌梗死。通过
实现这些具体目标,我们将获得实质性的新的机械性认识和意愿
开发新的和先进的心脏再生技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhong Wang其他文献
Zhong Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhong Wang', 18)}}的其他基金
Dissecting a post-translational modification code in cardiac reprogramming
剖析心脏重编程中的翻译后修饰代码
- 批准号:
10599325 - 财政年份:2022
- 资助金额:
$ 39万 - 项目类别:
Dissecting a post-translational modification code in cardiac reprogramming
剖析心脏重编程中的翻译后修饰代码
- 批准号:
10434240 - 财政年份:2022
- 资助金额:
$ 39万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8448103 - 财政年份:2012
- 资助金额:
$ 39万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8652492 - 财政年份:2012
- 资助金额:
$ 39万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8297158 - 财政年份:2012
- 资助金额:
$ 39万 - 项目类别:
Nanomaterials Synthesis, Fabrication, and Characterization
纳米材料的合成、制造和表征
- 批准号:
7737197 - 财政年份:2008
- 资助金额:
$ 39万 - 项目类别:
Nanomaterials Synthesis, Fabrication, and Characterization
纳米材料的合成、制造和表征
- 批准号:
7937750 - 财政年份:
- 资助金额:
$ 39万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 39万 - 项目类别: